Tandem Diabetes Care (NASDAQ:TNDM) Price Target Increased to $55.00 by Analysts at Barclays

Tandem Diabetes Care (NASDAQ:TNDM) had its target price hoisted by Barclays from $39.00 to $55.00 in a research note published on Monday, Benzinga reports. They currently have an overweight rating on the medical device company’s stock.

Several other equities research analysts have also commented on TNDM. StockNews.com raised shares of Tandem Diabetes Care from a sell rating to a hold rating in a research report on Friday, April 19th. Piper Sandler reiterated an overweight rating and issued a $50.00 price target (up from $35.00) on shares of Tandem Diabetes Care in a research report on Friday, May 3rd. Wells Fargo & Company raised shares of Tandem Diabetes Care from an equal weight rating to an overweight rating and boosted their price objective for the company from $21.00 to $45.00 in a research report on Monday, April 29th. SVB Leerink raised Tandem Diabetes Care from a market perform rating to an outperform rating and raised their target price for the stock from $34.00 to $45.00 in a report on Thursday, April 25th. Finally, Robert W. Baird boosted their price target on Tandem Diabetes Care from $28.00 to $36.00 and gave the company a neutral rating in a report on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $43.80.

Tandem Diabetes Care Trading Down 4.2 %

Shares of TNDM stock opened at $42.15 on Monday. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43. Tandem Diabetes Care has a 12-month low of $13.82 and a 12-month high of $47.00. The stock has a market capitalization of $2.72 billion, a P/E ratio of -19.42 and a beta of 1.10. The firm’s 50 day moving average is $33.22 and its 200 day moving average is $26.64.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The firm had revenue of $196.80 million during the quarter, compared to analysts’ expectations of $204.86 million. Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. Research analysts expect that Tandem Diabetes Care will post -1.62 earnings per share for the current year.

Institutional Trading of Tandem Diabetes Care

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Tandem Diabetes Care by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 7,021,906 shares of the medical device company’s stock worth $207,708,000 after purchasing an additional 18,571 shares during the period. Eminence Capital LP boosted its position in shares of Tandem Diabetes Care by 76.1% during the third quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock worth $114,028,000 after acquiring an additional 2,372,458 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Tandem Diabetes Care by 98.1% during the first quarter. Jennison Associates LLC now owns 2,556,124 shares of the medical device company’s stock worth $90,512,000 after acquiring an additional 1,265,534 shares during the last quarter. Paradice Investment Management LLC grew its stake in Tandem Diabetes Care by 23.9% during the third quarter. Paradice Investment Management LLC now owns 1,520,065 shares of the medical device company’s stock valued at $31,572,000 after acquiring an additional 293,250 shares in the last quarter. Finally, GW&K Investment Management LLC bought a new stake in Tandem Diabetes Care in the 4th quarter valued at $36,288,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.